Hongsheng Su
Geen lopende functies
Loopbaan van Hongsheng Su
Eerdere bekende functies van Hongsheng Su
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Corporate Officer/Principal | - | 29-06-2012 |
Statistieken
Internationaal
Canada | 2 |
Operationeel
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Health Technology |
- Beurs
- Insiders
- Hongsheng Su
- Ervaring